New insights into the pathogenesis and treatment of Takayasu arteritis

Expert Review of Clinical Immunology

Volumn 5, Issue 4, 2009, Pages 445-449

  Maksimowicz Mckinnon, Kathleen ^a  

^a UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

Aortoarteritis; Large vessel vasculitis; Pulseless disease; Takayasu arteritis

Indexed keywords

CHEMOKINE; CORTICOSTEROID; CYTOKINE; ETANERCEPT; FLUORODEOXYGLUCOSE F 18; GLUCOCORTICOID; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PACLITAXEL; PREDNISONE; RAPAMYCIN; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ANGIOPLASTY; AORTA; AORTA ARCH SYNDROME; ARTERITIS; ARTERY OCCLUSION; BARE METAL STENT; BIOLOGICAL THERAPY; CHRONIC DISEASE; COMPUTED TOMOGRAPHIC ANGIOGRAPHY; CORTICOSTEROID THERAPY; CYTOKINE PRODUCTION; DIAGNOSTIC IMAGING; DISEASE ACTIVITY; DRUG DOSE REDUCTION; DRUG ELUTING STENT; DRUG SUBSTITUTION; DRUG WITHDRAWAL; HUMAN; IMMUNE RESPONSE; IMMUNOSUPPRESSIVE TREATMENT; IN-STENT RESTENOSIS; INFLAMMATION; INTERVENTIONAL CARDIOVASCULAR PROCEDURE; MAGNETIC RESONANCE ANGIOGRAPHY; PATHOGENESIS; PATIENT MONITORING; POSITRON EMISSION TOMOGRAPHY; REVIEW; TREATMENT OUTCOME; VASCULITIS;

EID: 77649096155     PISSN: 1744666X     EISSN: None     Source Type: Journal    
DOI: 10.1586/eci.09.28     Document Type: Review

References (39)

1. Takayasu M. A case with peculiar changes of the retinal central vessels. Acta Societatis Opthalmological Japonicae 12, 554-555 (1908)
2. Savoy WE. Case of a young woman in whom the main arteries of both upper extremities and the left side of the neck were throughout completely obliterated. Med. Chir. Thrans. London 39, 205-219 (1856)
3. Morgagni GB. De sedibus et causis morborum per anatomen indagatis. Letter 30, Article 12 (1761)
4. Seko Y, Minota S, Kawasaki A et al. Perforin-secreting killer cell infiltration and expression of a 65-kD heat-shock protein in aortic tissue of patients with Takayasu's arteritis. J. Clin. Invest. 93, 750-758 (1994)
5. Chauhan, SK, Tripathy NK, Sinha N, Singh M, Nityanand S. Cellular and humoral immune responses to mycobacterial heat shock protein-65 and its human homologue in Takayasu's arteritis. Clin. Exp. Immunol. 138, 547-553 (2004)
6. Chauhan SK, Tripathy NK, Nityanand S. Antigenic targets and pathogenicity of anti-aortic endothelial cell antibodies in Takayasu's arteritis. Arthritis Rheum. 54, 2326-2333 (2006)
7. Park MC, Lee SW, Park YB, Lee SK. Serum cytokine profiles and their correlations with disease activity in Takayasu's arteritis. Rheumatology 45, 545-548 (2006)
8. Tripathy NK, Chandran V, Garq NK, Sinha N, Nityanand S. Soluble endothelial cell adhesion molecules and their relationship to disease activity in Takayasu's arteritis. J. Rheumatol. 35, 1842-1845 (2008)
9. Hoffman GS, Ahmed AE. Surrogate markers of disease activity in patients with Takayasu arteritis. A preliminary report from the International Network for the Study of Systemic Vasculitides (INSSYS). Int. J. Cardiol. 66(Suppl.), S191-S194 (1998)
10. Dhawan V, Mahajan N, Jain S. Role of C-C chemokines in Takayasu's arteritis disease. Int. J. Cardiol. 112, 105-111 (2006)
11. Tripathy NK, Chauhan SK, Nityanand S. Cytokine mRNA repertoire of peripheral blood mononuclear cells in Takayasu's arteritis. Clin. Exp. Immunol. 138, 369-374 (2004)
12. Saruhan-Direskeneli G, Bicakcigil M, Yilmaz V et al. Interleukin (IL)-12, IL-2, and IL-6 gene polymorphisms in Takayasu's arteritis from Turkey. Hum. Immunol. 67, 735-740 (2006)
13. Han JW, Shimada K, Ma-Krupa W et al. Vessel wall-embedded dendritic cells induce T-cell autoreactivity and initiate vascular inflammation. Circ. Res. 102, 546-553 (2008)
14. Pryshchep O, Ma-Krupa W, Younge BR, Goronzy JJ, Weyand CM. Vessel-specific toll-like receptor profiles in human medium and large arteries. Circulation 118, 1276-1284 (2008)
15. Kerr GS, Hallahan CW, Giordano J et al. Takayasu's arteritis. Ann. Int. Med. 120, 919-929 (1994)
16. Maksimowicz-McKinnon K, Clark TM, Hoffman GS. Limitations of therapy and a guarded prognosis in an American cohort of Takayasu arteritis patients. Arthritis Rheum. 56, 1000-1009 (2007)
17. Walter MA, Melzer RA, Schindler C et al. The value of F-18 FDG-PET in the diagnosis of large-vessel vasculitis and the assessment of activity and extent of disease. Eur. J. Nuc. Med. Mol. Imaging 32, 674-681 (2005)
18. Meave A, Soto ME, Reyes PA et al. Pre-pulseless Takayasu's arteritis. Evaluated with F-18 FDG positron emission tomography and gadolinium-enhanced magnetic resonance angiography. Tex. Heart Inst. J. 34, 466-469 (2007)
19. Pipitone N, Versari A, Salvarani C. Role of imaging studies in the diagnosis and follow-up of large vessel vasculitis: an update. Rheumatology 47, 403-408 (2008)
20. Iwabu M, Yamamoto Y, Dobashi H, Kameda T, Kittaka K, Nishiyama Y. F-18 FDG PET findings of Takayasu's arteritis before and after immunosuppressive therapy. Clin. Nuc. Med. 33, 872-873 (2008)
21. Walter MA. F-18 flurodeoxyglucose PET in large vessel vasculitis. Radiol. Clin. North Am. 45, 735-744 (2007)
22. Blockmans D, Bley T, Schmidt W. Imaging for large vessel vasculitis. Curr. Opin Rheumatol. 21, 19-28 (2009)
23. Arnaud L, Haroche J, Malek Z et al. Is 18-F-flurordeoxyglucose positron emission tomography scanning a reliable way to assess disease activity in Takayasu arteritis? Arthritis Rheum. 60, 1193-1200 (2009)
24. Molloy ES, Langford CA, Clark TM, Gota CE, Hoffman GS. Anti-tumor necrosis factor therapy in patients with refractory Takayasu arteritis: long term follow-up. Ann. Rheum. Dis. 67, 1567-1569 (2008)
25. Della Rossa A, Tavoni A, Merlini G et al. Two Takayasu arteritis patients successfully treated with infliximab: a potential disease-modifying agent? Rheumatology (Oxford) 44, 1074-1075 (2005)
26. Tanaka F, Kawakami A, Iwanaga N et al. Infliximab is effective for Takayasu arteritis refractory to glucocorticoid and methotrexate. Intern. Med. 45, 313-316 (2006)
27. Tato F, Rieger J, Hoffmann U. Refractory Takayasu's arteritis successfully treated with the human, monoclonal anti-tumor necrosis factor antibody adalimumab. Int. Angiol. 24, 304-307 (2005)
28. Shinjo S, Pereira R, Tizziani V, Radu AS, Levy-Neto M. Mycophenolate mofetil reduces disease activity and steroid dosage in Takayasu arteritis. Clin. Rheumatol. 26, 1871-1875 (2007)
29. Daina E, Schieppati A, Remuzzi G. Mycophenolate mofetil for the treatment of Takayasu arteritis: report of 3 cases. Ann. Intern. Med. 130, 422-426 (1999)
30. Tyagi S, Gambhir DS, Kaul UA et al. A decade of subclavian angioplasty: aortoarteritis versus atherosclerosis. Indian Heart J. 48, 667-671 (1996)
31. Fitzgibbon GM, Kafka HP, Leach AJ et al. Coronary bypass graft fate and patient outcome: angiographic follow up of 5065 grafts related to survival and reoperation in 1388 patients during 25 years. J. Am. Coll. Cardiol. 28, 616-626 (1996)
32. Fields C, Bower T, Cooper L et al. Takayasu's arteritis: operative results and influence of disease activity. J. Vasc. Surg. 43, 64-71 (2006)
33. Sharma S, Saxena A, Talwar KK et al. Renal artery stenosis caused by nonspecific arteritis (Takayasu disease): results of treatment with percutaneous transluminal angioplasty. Am. J. Roentgenol. 158, 417-422 (1992)
34. Amir O, Kar B, Civitello AB et al. Unprotected left main stent placement in a patient with Takayasu's arteritis: an unusual solution for an unusual disease. Tex. Heart Inst. J. 33, 253-255 (2006)
35. Kang WC, Han SH, Ahn TH, Shin EK. Successful management of left main coronary artery stenosis with a paclitaxeleluting stent in Takayasu's arteritis. Int. J. Cardiol. 108, 120-123 (2006)
36. Kang WC, Han SH, Oh KJ, Ahn TH, Shin EK. Implantation of a drug-eluting stent for the coronary artery stenosis of Takayau's arteritis. De novo and in-stent restenosis. Circulation 113, 735-737 (2006)
37. Furukawa Y, Tamura T, Toma M et al. Sirolimus-eluting stent for in-stent restenosis of left main coronary artery in Takayasu arteritis. Circ. J. 69, 752-755 (2005)
38. Munoz-Garcia AJ, Dominquez-Franco AJ, Alonso-Briales JH et al. Comparison of incidence and angiography patterns in definite thrombosis between drug-eluting and bare-metal stents. Int. J. Cardiol. (2008) (Epub ahead of print)
39. Win HK, Caldera AE, Maresh K et al. Clinical outcomes and stent thrombosis following off-label use of drug-eluting stents. JAMA 297, 2001-2009 (2007)